Quanterix to Participate at the Scotiabank Healthcare 1x1 Day

Rhea-AI Summary

Quanterix (NASDAQ: QTRX) has announced that its CEO, Masoud Toloue, and CFO, Vandana Sriram, will participate in the Scotiabank Healthcare 1x1 Day on June 20, 2024. Known for its ultrasensitive biomarker detection technology, Quanterix aims to showcase its advancements and strategies. For more details, visit their official website and explore their Simoa® technology.

Positive

• CEO and CFO participation in Scotiabank Healthcare 1x1 Day increases visibility.
• Opportunity to showcase Simoa® technology to potential investors and partners.
• Participation can enhance networking and strategic partnerships.

Negative

• No immediate financial or clinical achievements disclosed.
• Potentially high expectations without concrete deliverables may affect stock performance.

BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that Chief Executive Officer, Masoud Toloue, and Chief Financial Officer, Vandana Sriram, will attend the Scotiabank Healthcare 1x1 Day on June 20, 2024.

To learn more about Quanterix, visit www.quanterix.com/company. To learn more about Quanterix’s Simoa® technology, visit www.quanterix.com/simoa-technology.

About Quanterix

From discovery to diagnostics, Quanterix’s ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company’s Simoa ® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 2,900 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at https://www.quanterix.com or follow us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240617525411/en/

Media Contact:

PAN Communications

Maya Nimnicht

510-334-6273

quanterix@pancomm.com

Investor Relations Contact:

Quanterix

Francis Pruell

(508)-789-1725

ir@quanterix.com

Source: Quanterix Corporation

FAQ

When will Quanterix participate in the Scotiabank Healthcare 1x1 Day?

Quanterix will participate on June 20, 2024.

Who will represent Quanterix at the Scotiabank Healthcare 1x1 Day?

CEO Masoud Toloue and CFO Vandana Sriram will represent Quanterix.

What is the primary focus of Quanterix's participation in the Scotiabank Healthcare 1x1 Day?

The primary focus is to showcase Quanterix's ultrasensitive biomarker detection and Simoa® technology.

How might Quanterix's participation in the Scotiabank Healthcare 1x1 Day affect QTRX stock?

Participation could increase visibility and attract potential investors, potentially impacting QTRX stock positively.